SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Inclusion Criteria

• •Histologically-proven recurrent squamous cell carcinoma of the head and neck (SCCHN), who has received prior radiotherapy with or without chemotherapy. New primary is allowed if location is in a previously irradiated field. Biopsy is recommended for each recurrence but is not mandated per study. This will be at the discretion of the principal investigator.
• •Prior radiation dose of at least 50 Gy.
• •Disease confined to locoregional site and can be encompassed in a stereotactic body radiosurgery "portal"
• •Tumor must be deemed to be inoperable or unresectable either by clinical or radiographic criteria. These criteria include encasement of great vessels, vertebral invasion or undue peri-operative risk.
• •Prior surgery for recurrent or new SCCHN is allowed in previously irradiated patients. A minimum of 4 weeks should elapse between any surgery and treatment on study. However, high-risk pathologic features should be present, such as positive margins, positive lymphadenopathy, perineural or angiolymphatic invasion.
• •Karnofsky performance status \> 60 (ECOG 0-1)
• •Prior treatment with an EGFR Inhibitor is allowed if it was a part of prior curative therapy and was completed at least 30 days prior to commencement of study therapy
• •Any number of prior chemotherapy regimens are allowed
• •Measurable disease on imaging studies (MRI, CT, PET-CT or physical exam)
• •Age \> 18
• •Estimated life expectancy \> 12 weeks
• •No prior radiation therapy or chemotherapy within 1 month of study enrollment
• •ANC \> 1000, PLT\>75,000, Serum creatinine\<2.5 mg/dL, Bilirubin \<1.5 x upper limits of normal (ULN)
• •Diabetes must be controlled prior to PET-CT scanning (blood glucose \<200 mg/dL)
• •Ability to provide written informed consent